Home > Healthcare > Pharmaceuticals > Finished Drug Form > Ophthalmology Drugs Market

Ophthalmology Drugs Market Trends

  • Report ID: GMI6288
  • Published Date: Jan 2024
  • Report Format: PDF

Ophthalmology Drugs Market Trends

The rising prevalence of ocular disorders such as glaucoma, cataract, diabetic retinopathy, increasing healthcare expenditure and investments, rising research and development pertaining to the development of novel drugs, increasing focus on developing combination therapies, and increasing advancements in genomics and biomarker research are enabling more personalized approaches to ophthalmic treatments are propelling the market expansion.
 

  • For instance, according to The World Health Organization (WHO), approximately 2.2 billion people across the globe, are blind or have some vision impairment. Of these, 1 billion people have a condition that could be averted or is still untreated.
     
  • Further, WHO predicts that the number of individuals with vision impairment will increase by threefold by 2050, with the greatest increase in low- and middle-income nations. The increasing incidence of vision impairment along with the increasing awareness about eye care fuels the market growth.

 

As the global population continues to age, the prevalence of age-related eye conditions such as cataracts, age-related macular degeneration (AMD), and glaucoma is rising. The aging population is more susceptible to vision impairment and related eye diseases, leading to an increased demand for ophthalmic treatments.

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

Ophthalmology drugs industry was worth USD 31 billion in 2023 and is set to exhibit robust 5.1% CAGR from 2024 to 2032 attributed to the rising incidence of eye-related ailments along with increased R&D initiatives.

Prescription segment is poised to witness 5% CAGR between 2024 and 2032 owing to their increasing adoption due to the rise in conditions like AMD and diabetic retinopathy.

North America ophthalmology drugs market is set to expand at 4.8% CAGR from 2024-2032 driven by the significant prevalence of ophthalmic conditions in the region.

Some of the leading ophthalmology drug companies are AbbVie, Inc., Alcon Vision LLC, Bausch Health Companies, Inc., Bayer AG, Coherus BioSciences, F. Hoffmann-La Roche Ltd., Novartis AG, Pfizer, Inc., Regeneron Pharmaceuticals, Inc., Sun Pharmaceutical Industries Ltd., and Teva Pharmaceutical Industries Ltd.

Ophthalmology Drugs Market Scope

Buy Now

Immediate Delivery Available

Premium Report Details

  • Base Year: 2023
  • Companies covered: 12
  • Tables & Figures: 684
  • Countries covered: 19
  • Pages: 350
 Download Free Sample